The continued dismal outcomes for pancreatic cancer patients reveal our failure to understand molecular mechanisms critical to tumor progression and survival. Our group and others identified the RON tyrosine kinase receptor as an overexpressed protein and potential novel therapeutic target in pancreatic cancer. The working hypothesis of our laboratory is that RON receptor signaling is a potent promoter of invasive growth and survival in human pancreatic cancer that represents a potentially valuable therapeutic target. In support of this idea, we have recently shown that RON receptor downregulation can sensitize pancreatic cancer cells to gemcitabine in vivo. The relevance of RON to pancreatic cancer has also been borne out by recent publications documenting it as a commonly overexpressed protein in pancreatic cancer that may mediate cell survival in the setting of KRAS oncogene addiction. Our own preliminary work suggests that in the mouse, RON overexpression alone can mediate pancreatic carcinogenesis and that it may accelerate carcinogenesis in the setting of oncogenic Kras. Despite these findings, major gaps in our understanding of RON receptor biology and its role in pancreatic carcinogenesis remain. The goals of this application are;1) to directly test the hypothesis that RON signaling promotes progression of pancreatic intraepithelial neoplasia to pancreatic cancer, 2) to investigate mechanisms of RON ligand dependent and ligand independent activation in pancreatic cancer and, 3) to test the effects of a novel RON monoclonal antibody on the orthotopic growth of patient-derived pancreatic cancer xenografts in order to identify biomarkers associated with activated RON signaling and oncogene addiction. The findings from these studies will enhance our understanding of RON biology and thereby serve to inform the development and further testing of RON-directed therapies in pancreatic cancer.
The development of successful therapies for pancreatic cancer patients demands a more thorough understanding of the molecular mechanisms that drive tumor progression and survival. Our laboratory recently identified that the majority of pancreatic cancers overexpress the RON receptor tyrosine kinase and that RON signaling promotes pancreatic cancer cell invasive growth and survival. In this proposal, we will investigate how RON becomes activated and ultimately influences invasive growth of pancreatic cancer as well as determine biomarkers that may predict response to RON-directed therapies.
|Fox, Raymond G; Lytle, Nikki K; Jaquish, Dawn V et al. (2016) Image-based detection and targeting of therapy resistance in pancreatic adenocarcinoma. Nature 534:407-11|
|Chakedis, J; French, R; Babicky, M et al. (2016) A novel protein isoform of the RON tyrosine kinase receptor transforms human pancreatic duct epithelial cells. Oncogene 35:3249-59|
|Yeo, Dannel; He, Hong; Patel, Oneel et al. (2016) FRAX597, a PAK1 inhibitor, synergistically reduces pancreatic cancer growth when combined with gemcitabine. BMC Cancer 16:24|
|Buckel, Lisa; Savariar, Elamprakash N; Crisp, Jessica L et al. (2015) Tumor radiosensitization by monomethyl auristatin E: mechanism of action and targeted delivery. Cancer Res 75:1376-87|
|Seguin, Laetitia; Kato, Shumei; Franovic, Aleksandra et al. (2014) An integrin Î²â‚ƒ-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition. Nat Cell Biol 16:457-68|
|SchÃ¶nhuber, Nina; Seidler, Barbara; Schuck, Kathleen et al. (2014) A next-generation dual-recombinase system for time- and host-specific targeting of pancreatic cancer. Nat Med 20:1340-7|
|Kang, Chang Moo; Babicky, Michele L; Lowy, Andrew M (2014) The RON receptor tyrosine kinase in pancreatic cancer pathogenesis and its potential implications for future targeted therapies. Pancreas 43:183-9|
|Fujimura, Ken; Wright, Tracy; Strnadel, Jan et al. (2014) A hypusine-eIF5A-PEAK1 switch regulates the pathogenesis of pancreatic cancer. Cancer Res 74:6671-81|
|Yip-Schneider, Michele T; Wu, Huangbing; Hruban, Ralph H et al. (2013) Efficacy of dimethylaminoparthenolide and sulindac in combination with gemcitabine in a genetically engineered mouse model of pancreatic cancer. Pancreas 42:160-7|
|Garmy-Susini, Barbara; Avraamides, Christie J; Desgrosellier, Jay S et al. (2013) PI3KÎ± activates integrin Î±4Î²1 to establish a metastatic niche in lymph nodes. Proc Natl Acad Sci U S A 110:9042-7|
Showing the most recent 10 out of 17 publications